Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome

Fertility and Sterility

Volumn 103, Issue 3, 2015, Pages 795-801.e2

  Alpañés, Macarena ^a   Luque Ramírez, Manuel ^a   Martínez García, M Ángeles ^a   Fernández Durán, Elena ^a   Álvarez Blasco, Francisco ^a   Escobar Morreale, Héctor Francisco ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Androgen excess; dehydroepiandrosterone sulfate; glucose tolerance; insulin resistance; insulin sensitivity; obesity ity

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PRASTERONE SULFATE; TESTOSTERONE;

ADRENAL FUNCTION; ADRENAL HYPERANDROGENISM; ADULT; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERANDROGENISM; HYPERTENSION; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PREHYPERTENSION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; YOUNG ADULT; ADOLESCENT; ADRENAL CORTEX HYPERFUNCTION; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHILD; COMPLICATION; CROSS-SECTIONAL STUDY; METABOLIC DISEASES; METABOLISM; PHENOTYPE; RISK FACTOR;

ADOLESCENT; ADRENOCORTICAL HYPERFUNCTION; ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; METABOLIC DISEASES; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; YOUNG ADULT;

EID: 84926200169     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2014.12.105     Document Type: Article

References (44)

1. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, and W. Futterweit The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report Fertil Steril 91 2009 456 488
2. R.A. Wild, E.S. Umstot, R.N. Andersen, G.B. Ranney, and J.R. Givens Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism Am J Obstet Gynecol 146 1983 602 606
3. D.I. Hoffman, K. Klove, and R.A. Lobo The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women Fertil Steril 42 1984 76 81
4. E. Carmina, T. Koyama, L. Chang, F.Z. Stanczyk, and R.A. Lobo Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 167 1992 1807 1812
5. A. Kumar, K.S. Woods, A.A. Bartolucci, and R. Azziz Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS) Clin Endocrinol (Oxf) 62 2005 644 649
6. E. Carmina, and R.A. Lobo Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes J Endocrinol Invest 30 2007 111 116
7. K. Brennan, A. Huang, and R. Azziz Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome Fertil Steril 91 2009 1848 1852
8. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, and W. Futterweit Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline J Clin Endocrinol Metab 91 2006 4237 4245
9. S. Borruel, E. Fernández-Durán, M. Alpañés, D. Martí, F. Alvarez-Blasco, and M. Luque-Ramírez Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS) J Clin Endocrinol Metab 98 2013 1254 1263
10. J.M. Elbers, E.J. Giltay, T. Teerlink, P.G. Scheffer, H. Asscheman, and J.C. Seidell Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects Clin Endocrinol (Oxf) 58 2003 562 571
11. T. Apridonidze, P.A. Essah, M.J. Iuorno, and J.E. Nestler Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome J Clin Endocrinol Metab 90 2005 1929 1935
12. D. Panidis, D. Macut, K. Tziomalos, E. Papadakis, K. Mikhailidis, and E.A. Kandaraki Prevalence of metabolic syndrome in women with polycystic ovary syndrome Clin Endocrinol (Oxf) 78 2013 586 592
13. E. Cakir, M. Dogan, O. Topaloglu, M. Ozbek, E. Cakal, and M.G. Vural Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism Atherosclerosis 226 2013 291 295
14. C.K. Buffington, J.R. Givens, and A.E. Kitabchi Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females Diabetes 40 1991 693 700
15. M.J. Chen, C.D. Chen, J.H. Yang, C.L. Chen, H.N. Ho, and W.S. Yang High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome Hum Reprod 26 2011 227 234
16. J.F. Mortola, and S.S. Yen The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women J Clin Endocrinol Metab 71 1990 696 704
17. C. Meyer, B.P. McGrath, J. Cameron, D. Kotsopoulos, and H.J. Teede Vascular dysfunction and metabolic parameters in polycystic ovary syndrome J Clin Endocrinol Metab 90 2005 4630 4635
18. B.C. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, and R. Lobo Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group Fertil Steril 97 2012 28 38.e25
19. W.E. Rainey, B.R. Carr, H. Sasano, T. Suzuki, and J.I. Mason Dissecting human adrenal androgen production Trends Endocrinol Metab 13 2002 234 239
20. T.G. Pickering, N.H. Miller, G. Ogedegbe, L.R. Krakoff, N.T. Artinian, and D. Goff Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association Hypertension 52 2008 1 9
21. A. Vermeulen, L. Verdonck, and J.M. Kaufman A critical evaluation of simple methods for the estimation of free testosterone in serum J Clin Endocrinol Metab 84 1999 3666 3672
22. M. Matsuda, and R.A. DeFronzo Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp Diabetes Care 22 1999 1462 1470
23. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S11 S66
24. H.F. Escobar-Morreale, B. Roldan, R. Barrio, M. Alonso, J. Sancho, and H. de la Calle High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus J Clin Endocrinol Metab 85 2000 4182 4187
25. H.F. Escobar-Morreale, R. Sanchon, and J.L. San Millan A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs J Clin Endocrinol Metab 93 2008 527 533
26. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
27. D.A. Ehrmann, R.L. Rosenfield, R.B. Barnes, D.F. Brigell, and Z. Sheikh Detection of functional ovarian hyperandrogenism in women with androgen excess N Engl J Med 327 1992 157 162
28. H. Escobar-Morreale, F. Pazos, N. Potau, R. Garcia-Robles, J.M. Sancho, and C. Varela Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17 alpha Fertil Steril 62 1994 521 530
29. D. Meirow, I. Raz, O. Yossepowitch, A. Brzezinski, A. Rosler, and J.G. Schenker Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies? Hum Reprod 11 1996 1848 1853
30. D.E. Leszczynski, and R.M. Schafer Characterization of steroid hormone association with human plasma lipoproteins Steroids 54 1989 37 53
31. J.E. Nestler, J.N. Clore, and W.G. Blackard Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 6 1992 3073 3075
32. N. Kosus, A. Kosus, Z. Kamalak, D. Hizli, and N.O. Turhan Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome Gynecol Endocrinol 28 2012 611 614
33. R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, and W. Futterweit Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society J Clin Endocrinol Metab 95 2010 2038 2049
34. R.L. Barbieri, A. Makris, R.W. Randall, G. Daniels, R.W. Kistner, and K.J. Ryan Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism J Clin Endocrinol Metab 62 1986 904 910
35. J.E. Nestler, D.J. Jakubowicz, A.F. de Vargas, C. Brik, N. Quintero, and F. Medina Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system J Clin Endocrinol Metab 83 1998 2001 2005
36. H.F. Escobar-Morreale, and J.L. San Millan Abdominal adiposity and the polycystic ovary syndrome Trends Endocrinol Metab 18 2007 266 272
37. J.E. Nestler, L.P. Powers, D.W. Matt, K.A. Steingold, S.R. Plymate, and R.S. Rittmaster A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome J Clin Endocrinol Metab 72 1991 83 89
38. S.R. Plymate, L.A. Matej, R.E. Jones, and K.E. Friedl Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin J Clin Endocrinol Metab 67 1988 460 464
39. J. Yue, L. Wang, R. Huang, S. Li, J. Ma, and X. Teng Dehydroepiandrosterone-sulfate (DHEAS) promotes MIN6 cells insulin secretion via inhibition of AMP-activated protein kinase Biochem Biophys Res Commun 440 2013 756 761
40. J.L. Sanders, R.M. Boudreau, A.R. Cappola, A.M. Arnold, J. Robbins, and M. Cushman Cardiovascular disease is associated with greater incident dehydroepiandrosterone sulfate decline in the oldest old: the cardiovascular health study all stars study J Am Geriatr Soc 58 2010 421 426
41. E. Barrett-Connor, K.T. Khaw, and S.S. Yen A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease N Engl J Med 315 1986 1519 1524
42. L.E. Mitchell, D.L. Sprecher, I.B. Borecki, T. Rice, P.M. Laskarzewski, and D.C. Rao Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males Circulation 89 1994 89 93
43. E. Ingelsson, E.J. Schaefer, J.H. Contois, J.R. McNamara, L. Sullivan, and M.J. Keyes Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 298 2007 776 785
44. A. Gambineri, V. Vicennati, S. Genghini, F. Tomassoni, U. Pagotto, and R. Pasquali Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome J Clin Endocrinol Metab 91 2006 2295 2302